- Home
- POCI vs IMA Comparison
POCI vs IMA Comparison
Compare POCI & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | POCI | IMA |
|---|---|---|
| Founded | 1982 | 2019 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.2M | 54.8M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | POCI | IMA |
|---|---|---|
| Price | $5.06 | $5.50 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 36.1K | ★ 60.3K |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,091,269.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.55 | $3.94 |
| 52 Week High | $6.04 | $17.50 |
Technical Indicators
Market Signals| Indicator | POCI | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 67.22 | 45.35 |
| Support Level | $3.96 | $5.23 |
| Resistance Level | $5.32 | $7.17 |
| Average True Range (ATR) | 0.31 | 0.38 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 75.21 | 34.09 |
Price Performance
Historical ComparisonAbout POCI Precision Optics Corporation Inc.
Precision Optics Corp Inc is engaged in designing, developing, and manufacturing advanced optical instruments. It manufactures medical products such as endoscopes and endocouplers which incorporate various optical technologies for use in a variety of minimally invasive surgical and diagnostic procedures. The company also produces endoscopes for various applications as well as designs and manufactures custom optical medical devices to satisfy customers' specific requirements. In addition, the company manufactures and sells components and assemblies specially designed for industrial and military use. The company earns the majority of its revenue from the United States.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.